Insmed Inc (INSM)
69.29
+1.14
(+1.67%)
USD |
NASDAQ |
Nov 05, 16:00
70.35
+1.06
(+1.53%)
After-Hours: 19:14
Insmed Free Cash Flow: -636.03M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -636.03M |
| June 30, 2024 | -590.61M |
| March 31, 2024 | -588.55M |
| December 31, 2023 | -549.54M |
| September 30, 2023 | -524.40M |
| June 30, 2023 | -475.63M |
| March 31, 2023 | -453.16M |
| December 31, 2022 | -410.32M |
| September 30, 2022 | -387.75M |
| June 30, 2022 | -374.27M |
| March 31, 2022 | -347.99M |
| December 31, 2021 | -370.59M |
| September 30, 2021 | -353.62M |
| June 30, 2021 | -336.11M |
| March 31, 2021 | -295.02M |
| December 31, 2020 | -226.17M |
| September 30, 2020 | -215.30M |
| June 30, 2020 | -222.85M |
| March 31, 2020 | -275.66M |
| December 31, 2019 | -292.92M |
| September 30, 2019 | -310.39M |
| June 30, 2019 | -310.77M |
| March 31, 2019 | -277.89M |
| December 31, 2018 | -272.79M |
| September 30, 2018 | -247.80M |
| Date | Value |
|---|---|
| June 30, 2018 | -219.14M |
| March 31, 2018 | -198.07M |
| December 31, 2017 | -162.62M |
| September 30, 2017 | -171.43M |
| June 30, 2017 | -165.03M |
| March 31, 2017 | -158.12M |
| December 31, 2016 | -150.91M |
| September 30, 2016 | -120.13M |
| June 30, 2016 | -112.73M |
| March 31, 2016 | -108.12M |
| December 31, 2015 | -104.15M |
| September 30, 2015 | -90.67M |
| June 30, 2015 | -89.61M |
| March 31, 2015 | -82.93M |
| December 31, 2014 | -69.77M |
| September 30, 2014 | -69.47M |
| June 30, 2014 | -62.15M |
| March 31, 2014 | -49.10M |
| December 31, 2013 | -47.49M |
| September 30, 2013 | -42.41M |
| June 30, 2013 | -35.12M |
| March 31, 2013 | -37.00M |
| December 31, 2012 | -31.30M |
| September 30, 2012 | -28.70M |
| June 30, 2012 | -27.98M |
Free Cash Flow Range, Past 5 Years
-636.03M
Minimum
Sep 2024
-215.30M
Maximum
Sep 2020
-396.32M
Average
-372.43M
Median
Free Cash Flow Benchmarks
| Fulcrum Therapeutics Inc | -12.62M |
| Alnylam Pharmaceuticals Inc | 16.06M |
| Eli Lilly and Co | -2.275B |
| Bioventus Inc | 8.443M |
| Entrada Therapeutics Inc | -18.50M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -180.92M |
| Cash from Investing (Quarterly) | -1.003B |
| Cash from Financing (Quarterly) | 397.20M |
| Free Cash Flow Per Share (Quarterly) | -1.063 |
| Free Cash Flow to Equity (Quarterly) | 31.84M |
| Free Cash Flow to Firm (Quarterly) | -163.45M |
| Free Cash Flow Yield | -5.91% |